Culture Biosciences, a frontrunner in cloud-based biomanufacturing, has successfully closed its Series C fundraising round. The financing, which took place on December 16, 2025, was led by existing investors, including Northpond Ventures, Synthesis Capital, S32, and Cultivian Sandbox. This funding round demonstrates the unwavering confidence of current shareholders in the company’s growth trajectory and long-term vision.
The Series C financing will significantly boost the commercial rollout of Culture’s innovative hardware product, the Stratyx 250. This system is designed to provide scalable, automated, and digitally connected bioprocess capabilities tailored to meet the evolving demands of biologics, cell therapy, and advanced bioprocess development. In addition to hardware expansion, the investment will also support the ongoing development of the company’s AI-powered Console software ecosystem.
The Stratyx 250 signifies a leap forward in biomanufacturing technology. Engineered for versatility, it addresses critical requirements in a rapidly advancing industry. As biomanufacturing continues to evolve, Culture Biosciences aims to position itself at the forefront, ensuring that its technologies meet the needs of both current and future markets.
With this funding, Culture is set to enhance its operational capabilities and expand its market presence. The investment reflects a strong belief in the company’s potential to innovate within the biomanufacturing sector. As the need for advanced bioprocess solutions grows, Culture’s focus on integrating cloud technology with biomanufacturing processes positions it well for future success.
The company’s commitment to developing cutting-edge technologies is underscored by the support it has received from its investors. The backing from high-profile venture capitalists highlights the confidence in Culture’s strategic direction and operational model. With the Series C round successfully closed, Culture Biosciences is poised to accelerate its growth and drive advancements in the field of biomanufacturing.
As the industry continues to pivot towards automation and digital integration, Culture’s innovative solutions promise to lead the way, meeting the critical needs of a diverse range of clients and stakeholders in the biologics and cell therapy arenas.
